

**プログラム**

※本セミナーでとりあげられる演題は、2019年5月31日～6月4日に開催された米国臨床腫瘍学会（ASCO）の年次総会の演題の中から重要なものをASCOのプログラム委員会が指定し、日本臨床腫瘍学会のBest of ASCO部会が選定したものです。但し、IDに \* 印のある演題は日本臨床腫瘍学会のBest of ASCO部会が独自で選定したものです。

※ASCO年次総会後に採択演題が一部変更になることがあります。ご了承ください

7月6日（土曜日）

as of 2019/06/24

Time	講師	司会	ASCO演題		
			ID	Abstract Title	Author
9:30	開場				
10:30-10:40	<b>Welcome &amp; Introduction</b>				
	清田 尚臣 神戸大学医学部附属病院 / Best of ASCO部会 副部長				
10:40-11:05	<b>血液がん - Leukemia</b>		7000	Effect of gilteritinib on survival in patients with FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) AML who have common AML co-mutations or a high FLT3-ITD allelic ratio.	Mark Levis
	南 陽介 国立がん研究センター東病院	石塚 賢治 鹿児島大学大学院	7005	ENESTop 192-week results: Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib (NIL).	Timothy Hughes
			7006	End of phase I results of ZUMA-3, a phase 1/2 study of KTE-X19, anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in adult patients (pts) with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL).	Bijal Shah
11:05-11:15	Discussion: Q&A				
11:15-11:40	<b>血液がん - Lymphoma / Myeloma</b>		7502	Effect of fixed-duration venetoclax plus obinutuzumab (VenG) on progression-free survival (PFS), and rates and duration of minimal residual disease negativity (MRD-) in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) and comorbidities.	Kirsten Fischer
	山内 寛彦 国立がん研究センター東病院	石塚 賢治 鹿児島大学大学院	7506	Umbrolisib monotherapy demonstrates efficacy and safety in patients with relapsed/refractory marginal zone lymphoma: A multicenter, open label, registration directed phase II study.	Nathan Fowler
			8007	Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE) immunotherapy, in R/R multiple myeloma (MM) patients: Updated results of a first-in-human (FIH) phase I dose escalation study.	Max Topp
11:40-11:50	Discussion: Q&A				
11:50-12:10	<b>Melanoma</b>		9500	Phase 3 international trial of adjuvant whole brain radiotherapy (WBRT) or observation (Obs) following local treatment of 1-3 melanoma brain metastases (MBMs).	Gerald Fogarty
	並川 健二郎 国立がん研究センター中央病院	近藤 千紘 虎の門病院	9501	Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204).	Hussein Tawbi
12:10-12:20	Discussion: Q&A				
12:20-12:35	Break 15分				
12:35-13:25	<b>【演者】</b> 北野 滋久 国立がん研究センター中央病院	<b>【座長】</b> 南 博信 神戸大学	<b>ランチセミナー</b> がん免疫の抑制/逃避のメカニズムを理解する 共催：プリストル・マイヤーズ スクイブ株式会社/小野薬品工業株式会社		
13:25-13:40	Coffee Break 15分				
13:40-14:00	<b>Developmental Therapeutics</b>		3003*	Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors.	Marwan Fakih
	久保木 恭利 国立がん研究センター東病院	北野 滋久 国立がん研究センター中央病院	2511*	Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: Safety and preliminary efficacy in combination with anti-PD-1 agent.	Prasad S. Adusumilli
14:00-14:10	Discussion: Q&A				
14:10-14:35	<b>乳がん - Adjuvant</b>		503	Impact of clinical risk category on prognosis and prediction of chemotherapy benefit in early breast cancer (EBC) by age and the 21-gene recurrence score (RS) in TAILORx.	Joseph Sparano
	原 文堅 がん研究会有明病院	松本 光史 兵庫県立がんセンター	504	Benefit from letrozole as extended adjuvant therapy after sequential endocrine therapy: A randomized, phase III study of Gruppo Italiano Mammella (GIM).	Lucia Del Mastro
14:35-14:45	Discussion: Q&A				
14:45-15:20	<b>乳がん - Metastatic</b>		1000	SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx).	Hope Rugo
	尾崎 由記範 虎の門病院	藤澤 知巳 群馬県立がんセンター	1002	Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial.	Cristina Saura
			LBA1008	Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2- advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results.	Sara Hurvitz
15:20-15:30	Discussion: Q&A				
15:30-15:45	Break 15分				
15:45-16:25	<b>【演者】</b> 里見 絵理子 国立がん研究センター中央病院	<b>【座長】</b> 今井 久雄 群馬県立がんセンター	<b>スイーツセミナー</b> がん疼痛薬物治療 ～オピオイド有害事象管理 Up to date～ 共催：塩野義製薬株式会社		
16:25-16:40	Break 15分				
16:40-17:00	<b>肺がん</b> - Non-Small Cell Local-Regional/Small Cell/ Thoracic Cancers		8503	Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3).	David Kwiatkowski
	三浦 理 新潟県立がんセンター新潟病院	村上 晴泰 静岡県立静岡がんセンター	8504	Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study.	Tina Cascone
17:00-17:10	Discussion: Q&A				
17:10-17:50	<b>肺がん - Metastatic</b>		9000	RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucicromab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC).	Kazuhiko Nakagawa
	林 秀敏 近畿大学	衣斐 寛倫 愛知県がんセンター	9001	Phase III randomized trial comparing gefitinib to gefitinib with pemetrexed-carboplatin chemotherapy in patients with advanced untreated EGFR mutant non-small cell lung cancer (gef vs gef+C).	Vanita Noronha
			9002	ECOG-ACRIN 5508: Pemetrexed, bevacizumab or the combination as maintenance therapy for advanced non-squamous NSCLC.	Suresh Ramalingam
			9031*	Randomized phase III study comparing carboplatin plus pemetrexed followed by pemetrexed versus docetaxel in elderly patients with advanced non-squamous non-small-cell lung cancer (JCOG1210/WJOG7813L).	Isamu Okamoto
17:50-18:05	Discussion: Q&A				

**Best of ASCO® 2019 in Japan**  
a program licensed by the American Society of Clinical Oncology, Inc.

7月7日 (日曜日)

Time	講師	司会	ASCO演題		
7:30	開場		ID	Abstract Title	Author
8:00-8:40	<b>【演者】</b> 岡本 勇 九州大学病院	<b>【座長】</b> 後藤 功一 国立がん研究センター東病院	<b>モーニングセミナー</b> <b>進行肺がん薬物療法のトピックス</b> 共催：日本イーライリリー株式会社		
8:40-8:55	Break 15分				
8:55-9:15	<b>Sarcoma</b>				
	<b>内藤 陽一</b> 国立がん研究センター東病院	<b>小野澤 祐輔</b> 静岡県立静岡がんセンター	LBA3	ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS).	William Tap
			11001	STRASS (EORTC 62092): A phase III randomized study of preoperative radiotherapy plus surgery versus surgery alone for patients with retroperitoneal sarcoma.	Sylvie Bonvalot
9:15-9:25	Discussion: Q&A				
9:25-9:55	<b>泌尿器がん</b>				
	<b>松原 伸晃</b> 国立がん研究センター東病院	<b>田畑 健一</b> 北里大学	LBA2	Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial.	Christopher Sweeney
			5006	First results from TITAN: A phase III double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).	Kim Chi
			4503	CALGB 90601 (Alliance): Randomized, double-blind, placebo-controlled phase III trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma.	Jonathan Rosenberg
9:55-10:05	Discussion: Q&A				
10:05-10:20	Break(15分)				
10:20-10:40	<b>Symptoms and Survivorship</b>				
	<b>藤阪 保仁</b> 大阪医科大学附属病院	<b>井上 彰</b> 東北大学大学院	11503	A randomized, double-blind, placebo-controlled phase III trial evaluating olanzapine 5 mg combined with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy: J-FORCE Study.	Hironobu Hashimoto
			11506	Safety of pregnancy following breast cancer (BC) in patients (pts) carrying a BRCA mutation (mBRCA): Results of an international cohort study.	Matteo Lambertini
10:40-10:50	Discussion: Q&A				
10:50-11:20	<b>婦人科がん</b>				
	<b>原野 謙一</b> 国立がん研究センター東病院	<b>温泉川 真由</b> がん研有明病院	5506	Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase III SOLO3 trial.	Richard Penson
			5508	EWOC-1: A randomized trial to evaluate the feasibility of three different first-line chemotherapy regimens for vulnerable elderly women with ovarian cancer (OC): A GIG-ENGOT-GINECO study.	Claire Falandry
			5505	Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer. A randomized controlled chemotherapy-free study—NSGO-AVANOVA2/ENGOT-OV24.	Mansoor Mirza
11:20-11:30	Discussion: Q&A				
11:30-11:45	Break 15分				
11:45-12:35	<b>【演者】</b> 各務 博 埼玉医科大学国際医療センター	<b>【座長】</b> 高橋 和久 順天堂大学	<b>ランチセミナー</b> <b>免疫の理解により進化を続ける免疫チェックポイント阻害薬治療</b> <b>～単剤から複合免疫治療へ～</b> 共催：中外製薬株式会社		
12:35-12:50	Coffee Break 15分				
12:50-13:10	<b>頭頸部がん</b>				
	<b>門脇 重憲</b> 愛知県がんセンター中央病院	<b>清田 尚臣</b> 神戸大学医学部附属病院	6000	Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).	Danny Rischin
			6003	Gemcitabine and cisplatin (GP) induction chemotherapy (IC) plus concurrent chemoradiotherapy (CCRT) versus CCRT alone in locoregionally advanced nasopharyngeal carcinoma (NPC): A phase 3, multicenter, randomized controlled trial.	Jun Ma
13:10-13:20	Discussion: Q&A				
13:20-13:50	<b>消化器がん - Gastrointestinal Cancer</b>				
	<b>川上 尚人</b> 近畿大学医学部附属病院	<b>森実 千種</b> 国立がん研究センター中央病院	LBA4007*	Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.	Josep Tabernero
			3501	Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months {m}) for patients (pts) with high-risk stage II colorectal cancer (CC).	Timothy Iveson
13:50-14:00	Discussion: Q&A				
14:00-14:30	<b>消化器がん - Hepatobiliary/Pancreas Cancer</b>				
	<b>森実 千種</b> 国立がん研究センター中央病院	<b>川上 尚人</b> 近畿大学医学部附属病院	LBA4	Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial.	Hedy Kindler
			4000	APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma.	Margaret Tempero
			4003	ABC-06   A randomised phase III, multi-centre, open-label study of Active Symptom Control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.	Angela Lamarca
14:30-14:40	Discussion: Q&A				
14:40-14:50	<b>Closing Remarks</b> 佐治 重衛 福島県立医科大学 / Best of ASCO部会 部会長				